advertisement

WGC-2021

11.3.3 Apraclonidine, brimonidine (7)

Showing records 1 to 7

Display all abstracts in classification 11.3.3 Apraclonidine, brimonidine

Search within classification 11.3.3 Apraclonidine, brimonidine
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ; Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260
91036 Brimonidine-associated uveitis - a descriptive case series
Hopf S; Mercieca K
BMC Ophthalmology 2020; 20: 489
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Cardiel MJ; Fraile JM
Biomaterials science 2020; 8: 6246-6260
91036 Brimonidine-associated uveitis - a descriptive case series
Pfeiffer N
BMC Ophthalmology 2020; 20: 489
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mendez-Martinez S
Biomaterials science 2020; 8: 6246-6260
91036 Brimonidine-associated uveitis - a descriptive case series
Prokosch-Willing V
BMC Ophthalmology 2020; 20: 489
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mendez-Martinez S; Martinez-Rincon T; Martinez-Rincon T; Subias M; Subias M; Polo V; Ruberte J; Ramirez T; Vispe E; Luna C; Mayoral JA; Garcia-Martin E
Biomaterials science 2020; 8: 6246-6260

Issue 21-4

Change Issue


advertisement

Oculus